The 1,2,3-triazole–containing agent carboxyamidotriazole (CAI) could synergise with sorafenib to combat NSCLC by inhibiting NANOG and aggravating apoptosis (Ferreira et al., 2013; Chen et al., 2017). This evidence concerns the gene NANOG and non-small cell lung carcinoma.